How Has the Rotavirus Vaccine Market Size Evolved in Recent Years?
The rotavirus vaccine market has seen considerable growth due to a variety of factors.
• In recent times, there has been a substantial expansion of the rotavirus vaccine market. The expansion is set to continue, rising from $9.18 billion in 2024 to $10.14 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.5%.
Factors such as heightened awareness of rotavirus, enhancements in healthcare infrastructure, government-led vaccination initiatives, a surge in rotavirus infection cases, and an increase in birth rates all contributed to the growth experienced during the historical period.
What Are The Predictions for The Rotavirus Vaccine Market in the Coming Years?
The rotavirus vaccine market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for the rotavirus vaccine is anticipated to experience swift expansion in the following years, reaching $14.96 billion in 2029 with a compound annual growth rate (CAGR) of 10.2%.
The considerable growth during the projection period can be traced back to the surge in birth rates, scaling up of immunization campaigns, heightened emphasis on preventive healthcare, economic advancement, improved availability, as well as governmental strategies and funding. The forecast period is expected to witness significant trends such as the progression in vaccine technology, development in oral-dosing methods, enhanced vaccine compositions, combined vaccines, and the incorporation of digital health.
Which Drivers Are Accelerating Growth In The Rotavirus Vaccine Market?
The expected surge in birth rates is predicted to spur the expansion of the rotavirus vaccine market. Birth rates are defined as the number of live births per 1,000 individuals in a particular population over a specific timeframe, generally represented yearly. Factors such as enhanced economic stability, growth, and supportive policies like parental leave, child benefits, and childcare subsidies all influence birth rates. The administration of rotavirus vaccines decreases the occurrence of severe rotavirus gastroenteritis in infants, thus enhancing child health outcomes and minimizing the healthcare expenses linked to rotavirus infections. For example, a report issued by the Centers for Disease Control and Prevention, a national public health organization based in the US, stated that there was a 1% rise in registered birth rates in the United States in January 2023, tallying to 3,664,292, compared to the prior year. Consequently, the increase in birth rates will fuel the growth of the rotavirus vaccine market.
What Are The Core Segments Of The Global Rotavirus Vaccine Market?
The rotavirus vaccine market covered in this report is segmented –
1) By Type: Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb, Other Types
2) By Application: Adult, Pediatric
3) By End Users: Hospitals, Clinics, Academic Research
Subsegments:
1) By Rotarix: Dosing Schedule And Administration, Efficacy And Safety Profile, Target Demographics
2) By RotaTeq: Dosing Schedule And Administration, Efficacy And Safety Profile, Target Demographics
3) By Rotavac: Dosing Schedule And Administration, Efficacy And Safety Profile, Target Demographics
4) By Rotavin-M1: Dosing Schedule And Administration, Efficacy And Safety Profile, Target Demographics
5) By Lanzhou Lamb: Dosing Schedule And Administration, Efficacy And Safety Profile, Target Demographics
6) By Other Types: Emerging Rotavirus Vaccines, Combination Vaccines, Region-Specific Vaccines
Pre-Book The Rotavirus Vaccine Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Rotavirus Vaccine Industry?
Leading entities in the rotavirus vaccine market are switching to oral-dosing applicators to improve the effectiveness of vaccine delivery and promote patient adherence. These applicators are engineered to deliver liquid medicines or vaccines directly into the mouth, which ensures precise dosage and easy usage, particularly for infants and young children. For example, in November 2022, U.K.-based GSK plc, a pharmaceutical and biotechnological firm, secured approval from the U.S. Food and Drug Administration for a new applicator-only oral-dosing formulation of ROTARIX (Rotavirus Vaccine, Live, Oral). This liquid formulation defends against rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in infants. The fresh presentation of the vaccine streamlines its preparation for healthcare suppliers by removing the necessity for dose reconstruction at the point of administration.
Who Are the Key Players In The Rotavirus Vaccine Market?
Major companies operating in the rotavirus vaccine market are:
• Merck & Co. Inc.
• Sanofi S.A.
• Abbott Laboratories
• GlaxoSmithKline plc
• Daiichi Sankyo Company Limited
• Serum Institute of India Private Limited
• Sinovac Biotech Ltd.
• SK Chemicals Co Ltd.
• Bharat Biotech International Limited
• Walvax Biotechnology Co. Ltd.
• Indian Immunologicals Limited
• PT Bio Farma
• KFF Inc.
• Panacea Biotec Limited
• Sanyou Biopharmaceuticals Co. Ltd.
• Inovio Pharmaceuticals Inc.
• Hilleman Laboratories Private Limited
• China National Biotec Group Corporation
• Vabiotech
• Lanzhou Institute of Biological Products Co. Ltd.
• Nuvonis Pharmaceuticals Inc.
• Chengdu Institute of Biological Products Co. Ltd
What Are The Regional Insights Into The Rotavirus Vaccine Market?
North America was the largest region in the rotavirus vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rotavirus vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
